XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.25.1

Stockholders’ Equity | 3 Months Ended
--- | ---
Mar. 31, 2025
Stockholders’ Equity [Abstract] |
Stockholders’ equity | 7. Stockholders’ equity Warrants As of March 31, 2025, the following table summarizes the status of our outstanding and exercisable warrants and related transactions since December 31, 2024 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):
|  | Warrants outstanding and exercisable |
|  | Warrants |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value |  |  | Weighted Average Remaining Contractual Life (in Years) |
As of December 31, 2024 |  |  | 98 |  |  | $ | 63.33 |  |  |  | - |  |  |  | 5.6 |
As of March 31, 2025 |  |  | 98 |  |  | $ | 63.33 |  |  | $ | - |  |  |  | 5.3 |
Share-based compensation payment plans As of March 31, 2025, 57,230 shares of common stock were subject to outstanding awards under our share-based payment award plans and inducement grants (calculated using the base number of PSUs that may vest). As of March 31, 2025, 415,219 shares of common stock were available for future grants of share-based payment awards under the TherapeuticsMD, Inc. 2019 Stock Incentive Plan. The following table summarizes the status of our outstanding and exercisable options and related transactions since December 31, 2024 (in thousands, except weighted average exercise price and weighted average remaining contractual life data):
|  | Outstanding |  |  | Exercisable |
|  | Options Awards |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value |  |  | Weighted Average Remaining Contractual Life (in Years) |  |  | Options Awards |  |  | Weighted Average Exercise Price |  |  | Aggregate Intrinsic Value |  |  | Weighted Average Remaining Contractual Life (in Years) |
As of December 31, 2024 |  |  | 57 |  |  | $ | 270.33 |  |  | $ | — |  |  |  | 2.8 |  |  |  | 57 |  |  | $ | 270.20 |  |  | $ | — |  |  |  | 2.8 |
Expired |  |  | (5 | ) |  |  | 296.00 |  |  |  | — |  |  |  | — |  |  |  | (5 | ) |  |  | — |  |  |  | — |  |  |  | — |
As of March 31, 2025 |  |  | 52 |  |  | $ | 268.11 |  |  | $ | — |  |  |  | 2.7 |  |  |  | 52 |  |  | $ | 267.97 |  |  | $ | — |  |  |  | 2.7 |
The following table summarizes the status of our RSUs and related transactions since December 31, 2024 (in thousands, except weighted average grant date fair value):
|  | RSUs awards outstanding |
|  | RSUs |  |  | Weighted Average Grant Date Fair Value |  |  | Aggregate Intrinsic Value |
Balance, as of December 31, 2024 |  |  | 2 |  |  | $ | 21.78 |  |  | $ | 1.5 |
Vested |  |  | (2 | ) |  |  | 21.78 |  |  |  | — |
Balance, as of March 31, 2025 |  |  | — |  |  | $ | — |  |  | $ | — |
The following table summarizes the status of our PSUs and related transactions since December 31, 2024 (in thousands, except weighted average grant date fair value):
|  | PSUs(1) |  |  | Weighted Average Grant Date Fair Value |  |  | Aggregate Intrinsic Value |
Balance, as of December 31, 2024 |  |  | 5 |  |  | $ | 34.50 |  |  | $ | 4.47 |
Balance, as of March 31, 2025 |  |  | 5 |  |  | $ | 34.50 |  |  | $ | 4.84 |
(1) | The number of PSUs represents the base number of PSUs that may vest.
Share-based payment compensation cost Share-based payment compensation expense for PSUs is based on 100% vesting which was a part of the termination benefits for all employees who were terminated in 2022. We recorded share-based payment award compensation costs related to previously issued options, RSU and PSUs, as well as shares of common stock issued under our employee stock purchase plan (“ESPP”) totaling $23 thousand and $111 thousand for the three months ended March 31, 2025 and 2024, respectively. As of March 31, 2025, we had $1 thousand of unrecognized share-based payment award compensation cost related to unvested options, RSUs and PSUs as well as shares issuable under our ESPP, which may be adjusted for future changes in forfeitures and is included as additional paid-in capital in the accompanying condensed consolidated balance sheets. No tax benefit was realized due to a continued pattern of net losses. The unrecognized compensation cost of $1 thousand is expected to be recognized as share-based payment award compensation over a weighted average period of less than a month.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration